Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.68 |
| ▸ | F2 | P00734 | 3/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072434 | 0.91 | F10 (0.68) | F10F2SLC29A1 | |
| SCHEMBL6495088 | 0.89 | F10 (0.67) | F10F2SLC29A1 | |
| SCHEMBL6492417 | 0.87 | F10 (0.68) | F10F2SLC29A1 | |
| SCHEMBL18058761 | 0.86 | F10 (0.78) | F10F2SLC29A1 | |
| SCHEMBL6786084 | 0.86 | F10 (0.67) | F10F2SLC29A1 | |
| SCHEMBL6502111 | 0.86 | F10 (0.62) | F10F2SLC29A1 | |
| SCHEMBL15174759 | 0.85 | F10 (0.80) | F10F2SLC29A1 | |
| SCHEMBL17572203 | 0.85 | F10 (0.68) | F10F2SLC29A1 | |
| SCHEMBL1998685 | 0.85 | F10 (0.70) | F10F2SLC29A1 | |
| SCHEMBL6493754 | 0.85 | F10 (0.67) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | claimed |
| US-6750225-B2 | ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMS COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | F10 2/4885F2 12/4885SLC29A1 841/4885 |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | SERPINC1, SERPINE1, F11 | F10 31/4885F2 8/4885SLC29A1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.